ReviewDrugs2010
Role of cannabinoids in the treatment of pain and (painful) spasticity.
Review in Drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- [Cannabis and cannabinoids for the treatment of acute and chronic pain].Der Anaesthesist · 2021Pooled it
- The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.Current neurology and neuroscience reports · 2018Pooled it
- Differences in Plasma Exposure of Cannabidiol and Cannabidiolic Acid Following Oral Administration to Horses.Journal of veterinary pharmacology and therapeutics · 2026Article
- Overview: Chronic Pain and Cannabis-Based Medicines.Pharmacopsychiatry · 2024Review
- Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis.CNS drugs · 2024Review
- The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of SativexMini reviews in medicinal chemistry · 2024Review
- Chronic pain, chronic stress and substance use: overlapping mechanisms and implications.Frontiers in pain research (Lausanne, Switzerland) · 2023Review
- The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms.Life (Basel, Switzerland) · 2022Review
- The Efficacy of Cannabis in Reducing Back Pain: A Systematic Review.Global spine journal · 2022Article
- [The green rush-worse than feared? : Data on the misuse of medical cannabis].Schmerz (Berlin, Germany) · 2021Article
- Cannabinoid-Based Medicines and Multiple Sclerosis.Advances in experimental medicine and biology · 2021Review
- A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain.Journal of pain research · 2020Review
- The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain: How Cannabis Diminished Prescription Opioid Usage.Cannabis and cannabinoid research · 2020Article
- Antinociceptive and Abuse Potential Effects of Cannabinoid/Opioid Combinations in a Chronic Pain Model in Rats.Brain sciences · 2019Article
- [Cannabinoids in pain medicine].Schmerz (Berlin, Germany) · 2018Article
- Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis.Medicines (Basel, Switzerland) · 2018Review
- Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEXMedicines (Basel, Switzerland) · 2018Article
- Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.BMC psychiatry · 2018Article
- Anti-migraine effect of ∆European journal of pharmacology · 2018Article
- Therapeutic use of cannabis: Prevalence and characteristics among adults in Ontario, Canada.Canadian journal of public health = Revue canadienne de sante publique · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both the discovery of the endocannabinoid system (ECS) and its role in the control of pain and habituation to stress, as well as the significant analgesic and antihyperalgesic effects in animal studies, suggest the usefulness of cannabinoids in pain conditions. However, in human experimental or clinical trials, no convincing reduction of acute pain, which may be caused by a pronociceptive, ECS-triggered mechanism on the level of the spinal cord, has been demonstrated. In contrast, in chronic pain and (painful) spasticity, an increasing number of randomized, double-blind, placebo-controlled studies have shown the efficacy of cannabinoids, which is combined with a narrow therapeutic index. Patients with unsatisfactory response to other methods of pain therapy and who were characterized by failed stress adaptation particularly benefited from treatment with cannabinoids. None of the attempts to overcome the disadvantage of the narrow therapeutic index, either by changing the route of application or by formulating balanced cannabinoid preparations, have resulted in a major breakthrough. Therefore, different methods of administration and other types of cannabinoids, such as endocannabinoid modulators, should be tested in future trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.